Vigil Neuroscience rises on early-stage Alzheimer's drug trial data

Vigil Neuroscience

23/01/2025 14:40

** Shares of drug developer Vigil Neuroscience  VIGL.O  rise
10% to $2.25
    ** VIGL says its experimental Alzheimer's drug, VG-3927,
reduced key biomarker sTREM2 by up to 50% in cerebral spinal
fluid in early-stage trial
    ** Reduction in sTREM2 levels is expected to help slow
progression of Alzheimer's disease, as higher levels suggest
brain inflammation
    ** Co says VG-3927 was well-tolerated and has favorable
pharmacokinetic and pharmacodynamic profile in the trial
    ** VIGL plans to advance into mid-stage trial in Q3 2025
    ** 8 of 9 brokerages rate stock "buy" or higher and 1
"sell"; their median PT is $16.50 - data compiled by LSEG
    ** VIGL fell ~51% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))